XPH:ARCA-SPDR S&P Pharmaceuticals

ETF | Health | NYSE Arca

Last Closing Price

USD 41.13


0.00 (0.00)%

Market Cap

USD 0.29B



Average Target Price

Average Analyst Rating


STA Verdict



The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Inception Date: 19/06/2006

Primary Benchmark: S&P Pharms Select Industry TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.35%

Management Expense Ratio: 0.35 %

Unadjusted Closing Price

Adjusted Closing Price



Top Sectors


Top Regions


Share Volume

Relative Performance (Total Returns)

Relative Returns (From:    To: 2018-12-09 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV SPDR Select Sector Fund - Heal.. 0.14 %


USD 19.01B
VHT Vanguard Health Care 0.10 %


USD 8.82B
XBI SPDR Series Trust S&P Biotech 0.35 %


USD 4.06B
IHI iShares U.S. Medical Devices 0.43 %


USD 2.92B
FBT First Trust Amex Biotech Index.. 0.56 %


USD 2.64B
IYH iShares U.S. Healthcare 0.43 %


USD 2.45B
FXH First Trust Health Care AlphaD.. 0.62 %


USD 2.27B
IXJ iShares Global Healthcare 0.47 %


USD 1.74B
FHLC Fidelity MSCI Health Care Inde.. 0.08 %


USD 1.61B
IHF iShares U.S. Health Care Provi.. 0.43 %


USD 1.16B

ETFs Containing XPH


Market Performance

  Market Performance vs.
Industry/Classification (Health)
Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Capital Gain -5.45% 25% F 60% D-
Dividend Return 0.31% 32% F 4% F
Total Return -5.14% 14% F 51% F
Trailing 12 Months  
Capital Gain -4.42% 21% F 62% D-
Dividend Return 0.56% 35% F 7% F
Total Return -3.86% 14% F 52% F
Trailing 5 Years  
Capital Gain -6.65% 14% F 40% F
Dividend Return 3.27% 20% F 10% F
Total Return -3.38% 5% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain -0.81% 14% F 31% F
Dividend Return -0.19% 4% F 22% F
Total Return 0.62% 37% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 19.25% 36% F 36% F
Risk Adjusted Return -0.96% 4% F 22% F
Market Capitalization 0.50B 32% F 37% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.